Citations

Clear

2429 citation(s) found for "Shah, M".

Venetoclax Plus Hypomethylating Agent for 7‐ Versus 14‐ Versus 21‐ Versus 28‐Day Cycles in Newly‐Diagnosed Acute Myeloid Leukemia: ELN and Mayo Genetic Risk–Stratified Analysis in 540 Patients
Kumar, Sudhesh , Warraich, Momna , Fatima, Mahnoor , McCullough, Kristen , Al‐Kali, Aref , Alkhateeb, Hassan B. , Begna, Kebede H. , Mangaonkar, Abhishek A. , Saliba, Antoine N. , Litzow, Mark R. , Hogan, William J. , Shah, Meera , Patnaik, Mrinal M. , Pardanani, Animesh , Badar, Talha , Foran, James M. , Palmer, Jeanne, Yi, Cecilia Arana, Tefferi, Ayalew , Gangat, Naseema , Warraich, Momna , Hogan, William J , Shah, Mithun V , Foran, James M , McCullough, Kristen B , Saliba, Antoine N , Saliba, Antoine N , Palmer, Jeanne , Yi, Cecilia Arana

Mayo Clinic

American Journal of Hematology | September 18, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1002/ajh.70500 | PMID 42755126 Get It

ABSTRACT Patients with newly‐diagnosed acute myeloid leukemia (ND‐AML) derive variable survival benefit from venetoclax (Ven) plus hypomethylating agent (HMA) therapy, and the optimal Ven duration across genetic risk groups remains undefined. Among 540 ND‐AML patients receiving Ven‐HMA at Mayo Clinic, outcomes were compared across Ven 7‐ ( n = 33), 14‐ ( n = 117), 21‐ ( n = 96), and 28‐day ( n = 294) schedules during Cycle 1 and stratified by ELN 2024 and Mayo genetic risk groups. At a median follow‐up of 37.7 months, allogeneic stem cell transplant (ASCT) rates were similar across Ven duration groups (15%, 18%, 18%, and 20% for 7‐, 14‐, 21‐, and 28‐day; p = 0.86). Median transplant‐censored survival was comparable across Ven durations (13.3, 11.9, 16.8, and 13.2 months for 7, 14, 21, 28 days, respectively; p = 0.65), with outcomes driven by ELN risk (6.3, 11.5, 18.3 months for high, intermediate, low; p < 0.01) and Mayo genetic risk (6.9, 17.8 months, not reached; p < 0.01). Survival was comparable across Ven durations within ELN intermediate/low‐risk and all Mayo risk groups. Among ELN high‐risk patients, 14‐day Ven was associated with inferior transplant‐censored survival compared to 21‐ and 28‐day schedules ( p < 0.01). Notably, 30‐ and 60‐day mortality were higher with shorter Ven schedules (7‐day: 9%/18%; 14‐day: 7%/15%) versus 28‐day (2%/6%), which likely reflects treatment selection bias. In ND‐AML, no significant difference in transplant‐censored survival was observed across the 7‐, 14‐, 21‐, and 28‐day Ven schedules; prognosis was determined primarily by Mayo and ELN 2024 genetic risk rather than by Ven duration. Prospective trials are needed to establish risk‐adapted Ven dosing strategies.
Prospective randomised double‐blind trial: holmium laser lithotripsy with vs without Moses™ 2.0
Lee, Matthew , Forbes, Connor M. , Koyama, Tatsuki , Maciolek, Kimberly A , Nimmagadda, Naren , Lee, Aaron X , Hsi, Ryan , Koyama, Tatsuki , Forbes, Connor M , Lee, Matthew S , Chehroudi, Cyrus , Margolin, Ezra J , Chew, Ben H , Shah, Ojas , Miller, Nicole L , Nimmagadda, Naren , Reed, Amy M., Hsi, Ryan S. , Chew, Ben H. , Bechis, Seth K. , Humphreys, Mitchell R. , Lipkin, Michael E. , Monga, Manoj , Shah, Ojas , Stern, Karen , Sur, Roger L. , Sivalingam, Sri , Miller, Nicole L.

Mayo Clinic

BJU International | September 14, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1111/bju.70446 | PMID 42733216 Get It

Objective To assess the effect of Moses™ 2.0 (Lumenis Be Ltd., Yokneam Illit, Israel; Boston Scientific, Marlborough, MA, USA) for lithotripsy of renal stones of 8–20 mm in diameter on operative time, surgeon workload, and retropulsion. Subjects/Patients and Methods In our multicentre, randomised, double‐blind clinical trial, patients were randomised 1:1 to standard or Moses 2.0 laser lithotripsy and stratified by stone size. Patients and surgeons were blinded to laser modality. Primary outcomes were total operative time as well as surgeon workload assessed by the National Aeronautics and Space Administration‐Task Load Index (NASA‐TLX). Secondary outcomes were stone retropulsion evaluated by blinded video review and postoperative clinical outcomes. Linear regression modelling was used for analysis. Results A total of 153 patients (79 Standard, 74 Moses 2.0) with similar clinical, stone, and operative characteristics were evaluated. There was no significant difference in operative times between the Standard and Moses 2.0 groups ( P = 0.73). Moses 2.0 was associated with lower effort, frustration, mental, physical, and temporal workload, as well as higher rated overall performance compared to the standard laser. Video review demonstrated no difference in rates of retropulsion ( P = 0.13). Complication rates (Standard: 13%; Moses 2.0: 10%) and stone‐free rates (Standard: 51%; Moses: 2.0 55%) were comparable. Conclusion Our study evaluated the impact of Moses 2.0 technology on high‐powered renal stone dusting, constituting the largest double‐blind trial of its kind to date. There was insufficient evidence to suggest any difference in operative times or clinical outcomes when using Moses 2.0 compared to standard laser lithotripsy. Moses 2.0 was associated with reduced surgeon workload, which has implicit impact on surgeon wellness.
Gender Differences in Treatment Burden and Care Sustainability Among Adults Living With Diabetes
Montori, Víctor M. , Montori, Victor M , Rivadeneira, Francisco D., Rabeaa, Omar M., Shah, Brandon N., Branda, Megan E. , Brito, Juan P.

Mayo Clinic

No container title available | September 11, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.09.08.26362531 Get It

ABSTRACT Objective Women carry disproportionate shares of caregiving and other life demands that may compound the work of diabetes self-management. We sought to examine gender differences in overall and digital treatment burden and their key contributors. Research Design and Methods Cross-sectional analysis of two cohorts of adults with type 1 or type 2 diabetes attending outpatient endocrinology visits who completed the Treatment Burden Questionnaire Plus Digital (TBQ+D) (n=472). Multivariable regression estimated gender differences in overall and digital treatment burden, ability to live a normal life, and sustainability of current self- care effort, adjusting for age, diabetes type, insulin intensity, HbA1c, and cohort. Item-level analyses identified contributors to observed differences. Results Compared to men, women reported higher median overall treatment burden (33 vs 20, adjusted mean difference 10.6 points, 95% CI 5.1–16.3; p <.0001) and digital treatment burden (13 vs 7, adjusted mean difference 3.5 points, 95% CI 1.1–6.1; p =.009). They also had higher odds of not living a normal life (OR 1.77, 95% CI 1.18–2.67; p =0.006) and difficulty sustaining current self-care efforts indefinitely (OR 2.01, 95% CI 1.10–3.66; p =0.023). Digital burden differences were concentrated in annoyance, precautions, and time and effort required to use digital medicine tools, whereas contributors to differences in overall burden varied, with relationships, self-monitoring, and injections contributing most. Conclusions After adjusting for treatment intensity and other factors, women living with diabetes were twice as likely to be overwhelmed by diabetes care than men. Their greater vulnerability to treatment burden demands healthcare service redesign and individualization of plans of care that minimally disrupt patients’ and caregivers’ lives. ARTICLE HIGHLIGHTS Why did we undertake this study? Women may experience greater treatment burden across chronic conditions, reflecting competing (caregiving) demands that reduce capacity for self-management. Gender differences in diabetes, especially digital burden, remain unclear. What is the specific question we wanted to answer? Do women with diabetes experience greater overall and digital treatment burden than men? What did we find? Women reported greater overall and digital burden and more difficulty living a normal life and sustaining care than men. Differences were larger for digital annoyance, precautions, and effort, plus relationships, self-monitoring, and injections. What are the implications? Treatment burden cannot be inferred from treatment intensity alone. Diabetes care should consider whether treatment work fits within each patient’s life and can be sustained. Women with diabetes may be particularly vulnerable to becoming overwhelmed by the work of diabetes care.
Recent Progress in the Field of Artificial Organs
Curran, Brett F., Shah, Aakash M., Curran, Brett , Ursoleo, Jacopo D’Andria , Shah, Aakash M., Treffalls, John A.

Mayo Clinic

Artificial Organs | September 10, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1111/aor.70235 Get It

FANCM restrains structural genome evolution and defines a synthetic lethal dependency in BRCA1 -deficient breast cancer
Panday, Arvind , Ramadan, Farah, Shah, Sameer Bikram , Subedi, Ujwal, Stephens, Zachary, Venkatachalam, Annapoorna , Yadav, Neelima, Pandit, Vickky, Dubey, Sadhana, Latka, Sarah, Villanueva, Hugo , Dubey, Sadhana, Latka, Sarah , Kaufmann, Scott H. , Panday, Arvind

Mayo Clinic

No container title available | September 10, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.09.06.749689 | PMID 42818548 Get It

Abstract BRCA1 -deficient cancers experience persistent replication stress and structural genome instability yet retain the capacity for sustained proliferation, implying reliance on compensatory genome-maintenance mechanisms. Here, we establish BRCA1–FANCM synthetic lethality in human BRCA1 -deficient breast cancer and exploit temporally controlled FANCM depletion to capture genome evolution over successive cell divisions before declining cellular fitness becomes limiting. We show that FANCM restrains genome-wide structural variation in BRCA1 -deficient breast cancer cells under endogenous replication stress. FANCM loss amplifies the characteristic BRCA1 -associated short tandem duplication (TD) phenotype while permitting larger, including megabase-scale, TDs and diverse rearrangements to emerge. Newly emerged TDs preferentially associate with Pol II-occupied regions, and FANCM depletion increases proximity between the replication machinery and elongating RNAPII in BRCA1 -mutant breast cancer cells, linking FANCM-mediated genome protection to transcription–replication encounters. BRCA1 -altered human tumors with low FANCM expression recapitulate key features of this phenotype, while genome–transcriptome integration links newly emerged SVs to configuration-dependent local transcriptional changes. Together, these findings establish FANCM as a replication-stress safeguard coupling survival to restraint of structural genome evolution.
Infections in ECMO: A Comprehensive Review of the Epidemiology, Diagnosis, Management and Prevention
Marcus, Joseph E , Shah, Aditya, O'Neil, Erika R , Marcus, Joseph , MacLaren, Graeme , Barbaro, Ryan P.

Mayo Clinic

Journal of Intensive Care Medicine | September 8, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1177/08850666261487150 | PMID 42709717 Get It

Extracorporeal membrane oxygenation (ECMO) provides life support for severe respiratory and cardiac failure, including failure from severe infection such as sepsis and acute respiratory distress syndrome. Additionally, ECMO-acquired infections are frequent and associated with prolonged hospitalization, increased healthcare utilization, and higher mortality. This review summarizes current evidence regarding the epidemiology, pathophysiology, diagnosis, prevention, and management of infectious adverse events during ECMO. Future work should aim to refine ECMO-related infectious adverse event definitions, improve harmonized multicenter data collection, and to invest in high-quality, well-designed studies.
Clinical characteristics, susceptibility profiles, and outcomes of infection with Alternaria species: a 14-year retrospective study
Hindy, Joya-Rita , Auyeung, Austin B , Stevens, Ryan W. , Ranganath, Nischal , Deml, Sharon M., Wengenack, Nancy L. , Shah, Aditya , Shah, Aditya S , Ranganath, Nischal , Stevens, Ryan W

Mayo Clinic

Medical Mycology | September 6, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1093/mmy/myag093 | PMID 42704634 Get It

Abstract Alternaria spp. are dematiaceous ascomycetes that can cause opportunistic infections in immunocompromised hosts. They are challenging to identify and treat. However, optimal antifungal therapy remains undefined. We retrospectively reviewed antifungal susceptibilities (AST) of all Alternaria spp. isolates from adults at a tertiary care center between 2011 and 2025. We evaluated culture sources, minimum inhibitory concentration (MIC) and minimal effective concentration (MEC) distributions, and MIC₅₀/MIC₉₀ and MEC50/MEC90 values. Clinical characteristics, treatment measures, and outcomes of patients with clinically significant Alternaria spp. infections were described. Forty-one patients had Alternaria spp. isolated, most commonly from skin (n = 13), bone/joint (n = 5), nail (n = 3), or cornea (n = 3). Posaconazole and itraconazole demonstrated low MICs (MIC₅₀/MIC₉₀: 0.06/0.5 and 0.25/0.5 µg/mL, respectively). Voriconazole and isavuconazole showed higher MIC₅₀/MIC₉₀ (1/2 and 2/4 µg/mL). Caspofungin (0.125/0.5 µg/mL) and amphotericin B (0.25/1 µg/mL) had low MICs and MECs.s. Alternaria spp. represented clinically significant infection in 27 cases (66%); 26% were solid organ transplant recipients and 15% had hematologic malignancies. Other risk factors included preceding trauma (22%) and autoimmune disease (15%). Posaconazole was the most frequently used empiric agent (6, 32%). Following AST results, 14 patients (52%) received oral antifungal therapy; posaconazole was used in all 14. In addition, 7 patients (26%) received combination therapy with IV amphotericin B. Adjunctive surgery occurred in 14 cases (52%). Five patients (19%) died before completing therapy; Alternaria infections occurred predominantly in immunocompromised hosts and were frequently managed with posaconazole and surgery. Interpretive criteria for Alternaria spp. are needed to guide empiric and definitive therapy.
Older Age, STAG2 , and DNMT3A Mutations Predict Superior Posttransplant Survival in Newly Diagnosed Acute Myeloid Leukemia Treated With Venetoclax Plus Hypomethylating Agents
Warraich, Momna , Kumar, Sudhesh , Fatima, Mahnoor , McCullough, Kristen , Al‐Kali, Aref , Begna, Kebede H. , Mangaonkar, Abhishek A. , Saliba, Antoine N. , Matin, Aasiya , Litzow, Mark R. , Patnaik, Mrinal M. , Pardanani, Animesh , Foran, James M. , Sproat, Lisa, Khera, Nandita , Tefferi, Ayalew , Gangat, Naseema , Saliba, Antoine N. , Alkhateeb, Hassan B , Mangaonkar, Abhishek A. , Saliba, Antoine N , Matin, Aasiya , Litzow, Mark R. , Hogan, William J , Shah, Mithun V , Patnaik, Mrinal , Pardanani, Animesh , Foran, James M , Khera, Nandita , Tefferi, Ayalew , Gangat, Naseema , McCullough, Kristen B , Saliba, Antoine N , Alkhateeb, Hassan B. , Hogan, William J. , Shah, Meera

Mayo Clinic

American Journal of Hematology | August 23, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1002/ajh.70480 | PMID 42633550 Get It

ABSTRACT Venetoclax (Ven) plus hypomethylating agents (HMA) is standard frontline therapy for newly diagnosed AML (ND‐AML) patients unfit for intensive chemotherapy and is also considered in younger, fit patients. However, consolidation with allogeneic stem cell transplant (ASCT) is often required to secure durable remission. The current study examines posttransplant outcomes in patients with ND‐AML treated with frontline Ven‐HMA who subsequently underwent ASCT. A total of 111 ND‐AML patients (58% male, 60% secondary/therapy‐related, median age 70 years [range, 37–80]) received a median of 3 cycles of Ven‐HMA. Mutations at the time of diagnosis included RUNX1 (18%), SRSF2 (17%), TP53 (16%), ASXL1 , IDH2 , K/NRAS , TET2 (14% each), STAG2 (11%), DNMT3A (8%). All patients were in CR/CRi at the time of transplant including 88% after Ven‐HMA. Measurable residual disease (MRD) by flow cytometry was detectable in 18/76 (24%) patients. Donors were mostly HLA‐matched unrelated (75%); 51% receiving fludarabine/melphalan conditioning and 67% posttransplant cyclophosphamide. At a median follow‐up of 15 months, 42 (38%) of patients have died and 18 (16%) experienced posttransplant relapse. Median posttransplant survival was not reached (NR), with 1‐, 2‐, 3‐year survival rates of 69%/60%/57%, respectively. On multivariate analysis, age ≥ 65 years, STAG2 mutation ( STAG2 MUT ) , and DNMT3A MUT were associated with superior posttransplant survival. Patients were stratified into low‐ (0–1 point), intermediate‐ (2 points), and high‐risk (3 points); age < 65 years, STAG2 wild type, and DNMT3A wild type, with 3‐year survival rates of 89%, 59%, and 19%, respectively ( p < 0.01). Taken together, age, STAG2 MUT and DNMT3A MUT stratified posttransplant survival in Ven‐HMA treated patients with ND‐AML.
Ethanol reshapes FFC-driven steatohepatitis through time-dependent fibrosis and lipid-droplet remodeling
Weninger, Jasmin , Lee, Amani L. , Marek, George , Lange, Naomi F. , Mauer, Amy S. , Puri, Gyanendra, Shah, Vijay H. , Malhi, Harmeet , Lee, Amani , Marek, George W , Lange, Naomi , Malhi, Harmeet

Mayo Clinic

American Journal of Physiology-Gastrointestinal and Liver Physiology | August 22, 2026 | Volume: 331 | Issue: 4 | Pages: G399-G413

10.1152/ajpgi.00223.2026 | PMID 42631413 Get It

This study presents a refined murine MetALD model designed to distinguish ethanol-modified features from FFC-driven metabolic steatohepatitis. Chronic ethanol did not uniformly worsen liver injury. Instead, it selectively modified disease trajectory through greater early collagen-positive fibrotic remodeling, altering lipid-droplet architecture, and context-dependent inflammatory chemokine signaling. By 24 wk, FFC and FFC/ethanol injury programs converged, supporting MetALD as a timing- and pathway-dependent modification of metabolic steatohepatitis.
Academic societies in medicine: functions, benefits, challenges, and opportunities
Robiner, William N. , Brodell, Robert T. , Dupras, Denise M. , Shah, Neel , Weissman, Eric , Garrod, Andrea S. , Shaffer, Laura A. , Abdallah, Claude , Lumpkins, Kimberly , Shah, Neel B , Lumpkins, Kimberly M

Mayo Clinic

Academic Medicine | August 22, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1093/acamed/wvag262 | PMID 42629334 Get It

Abstract Health and biomedical science-related academic societies have played significant roles in the development and evolution of science and medicine, as well as the evolution of disciplines, including the diversification of medicine into specialties and subspecialties. They have also had formative roles in the development of clinical practice, professionalism, and training standards. The communities they establish promote knowledge creation and dissemination, provide career and professional development opportunities, articulate professional matters, offer networking opportunities, provide recognition, support members, and perform public engagement and advocacy work. They also play increasingly important roles in educating the public and disseminating objective, evidence-based medical and scientific information. Academic societies face challenges related to membership (recruiting new members and engaging and retaining current members), technology, hosting meetings and conferences, generational shifts (e.g., in demographics and attitudes toward working conditions, career paths, work-life integration), costs and logistics related to operations, and morale within institutions and professions. The Council of Faculty and Academic Societies of the Association of American Medical Colleges plays a unique role in supporting academic medical and related societies by providing an interprofessional forum for their interaction and dialogue, and is a vehicle for asserting their collective voice. To the extent that past is prologue, future advances in health care and science will depend, in part, on the resilience of academic societies and on the health professional workforces that they nourish.